Efficacy and safety of TACE combined with anlotinib compared with TACE alone among patients with intermediate or advanced hepatocellular carcinoma (HCC): A randomized, controlled, phase II clinical study.

被引：0
|
作者：
Zeng, Hui
Shao, Guoliang
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med, Dept Intervent Radiol,Canc Hosp, Hangzhou, Peoples R China
[2] Zhejing Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
581
引用
收藏
页码：581 / 581
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety analysis of TACE plus PEI plus lenvatinib compared with TACE plus lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study
    Lu, Haohao
    Zheng, Chuansheng
    Liang, Bin
    Xia, Xiangwen
    Fan, Hongjie
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.
    Xia, Yongxiang
    Wang, Ping
    Pu, Liyong
    Qian, Xiaofeng
    Cheng, Feng
    Wang, Ke
    Zhang, Chuanyong
    Li, Donghua
    Li, Xiangcheng
    Zhang, Feng
    Zhao, Jie
    Li, Si
    Xi, Wenjing
    Wang, Xuehao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Advanced hepatocellular carcinoma (HCC) treated with sunitinib (Su) and transarterial chemoembolization (TACE): Phase II trial final report
    Iyer, Renuka V.
    Tomaszewski, Garin
    Wu, Yuhsin V.
    Kuvshinoff, Boris W.
    Groman, Adrienne E.
    Khushalani, Nikhil I.
    Grande, Catherine
    Zagst, Patricia D.
    Clark, Kimberly
    Fetterly, Gerald J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [44] Efficacy and safety of apatinib combined with TACE in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
    Zhang, Wei
    Yan, Zhiping
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
    Cheng, Ann-Lii
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Loembe, Arsene-Bienvenu
    Hocke, Julia
    Choi, Caren
    Ryoo, Baek-Yeol
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [46] TACE 2: A randomized placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC) Background
    Meyer, Tim
    Fox, Richard
    Ma, Yuk Ting
    Ross, Paul J.
    James, Martin
    Strugess, Richard
    Stubbs, Clive
    Wall, Lucy
    Watkinson, Anthony
    Hacking, Nigel
    Evans, T. R. Jeffry
    Collins, Peter
    Hubner, Richard
    Cunningham, David
    Primrose, John Neil
    Johnson, Philip James
    Palmer, Daniel H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.
    Chan, Stephen Lam
    Yeo, Winnie
    Mo, Frankie
    Li, Leung
    Lee, Kit Fai
    Chan, Anthony W. H.
    Hui, Edwin Pun
    Lai, Paul B. S.
    Mok, Tony
    Chan, Anthony T. C.
    Yu, Simon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma
    Zhou, Bo
    Yan, Zhiping
    Liu, Rong
    Shi, Peng
    Qian, Sheng
    Qu, Xudong
    Zhu, Liang
    Zhang, Wei
    Wang, Jianhua
    [J]. RADIOLOGY, 2016, 280 (02) : 630 - 639
  • [49] Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
    Han, Y.
    Cao, G.
    Sun, B.
    Wang, J.
    Yan, D.
    Xu, H.
    Shi, Q.
    Liu, Z.
    Xu, L.
    Liu, B.
    Zou, Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1309 - S1309
  • [50] Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
    Shao, Guoliang
    Zeng, Hui
    Zhang, Zhewei
    Luo, Jun
    Zhang, Dinghu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 499 - 499
12345